BRAF and melanoma: Most recently, an HSP90 inhibitor XL888 in combination with a v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor Vemurafenib had clinical activity in patients with advanced BRAF-V600-mutant melanoma with a tolerable side-effect profile [198], while it was indicated that HSP90 inhibitors warrant further evaluation in combination with current standard-of-care (SOC) BRAF plus MEK inhibitors in BRAF-V600-mutant melanoma (Table 5).